Igg4 Related Disease clinical trials

Explore recruiting igg4 related disease clinical trials.

Recruiting igg4 related disease studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Igg4 Related Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Deciphering B and T cell Co-stimulation for the Targeted Treatment of IgG4-Related Disease

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBEXELIMAB IN PATIENTS WITH IGG4-RELATED DISEASE (INDIGO)

Spain, Germany, Netherlands, Italy, Sweden, Hungary +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy and Safety in IgG4-Related Disease.

Netherlands, Italy, Germany, Poland, Spain, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, Phase 3, double-blind, 52-week study to evaluate the efficacy and safety of rilzabrutinib (SAR444671) compared to placebo in adult participants with active IgG4-related disease

Netherlands, Spain, France, Belgium, Sweden, Germany +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Drug Rediscovery for rare Immune Mediated Inflammatory Diseases (DRIMID)

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Prospective diagnostic performance of PET/CT using the novel fibroblast imaging tracer 18F-AlF-FAPI-74 versus standard of care 18F-FDG in inflammatory disorders.

Belgium

Phase II and Phase III (Integrated) EU CTIS Study details

Igg4 Related Disease clinical trials

Recruiting igg4 related disease studies right now

Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease

Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases

Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement

A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases

Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease

A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease

Short-term Glucocorticoid Combined with MMF for IgG4-RD

A Study of Efgartigimod in Patients With IgG4-Related Disease

The Investigators Will Evaluate the Diagnostic Performance of [18F]-AlF-FAPI-74 PET/CT in Inflammatory Disorders and Compare it With the Current Gold Standard for Inflammation, FDG PET/CT, in Three Patient Cohort: Patients Presenting With Fever of Unknown Origin, IgG4-RD and AxSpA.

Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease

the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

Also recruiting in Europe

Deciphering B and T cell Co-stimulation for the Targeted Treatment of IgG4-Related Disease

A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBEXELIMAB IN PATIENTS WITH IGG4-RELATED DISEASE (INDIGO)

A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy and Safety in IgG4-Related Disease.

A randomized, Phase 3, double-blind, 52-week study to evaluate the efficacy and safety of rilzabrutinib (SAR444671) compared to placebo in adult participants with active IgG4-related disease

Drug Rediscovery for rare Immune Mediated Inflammatory Diseases (DRIMID)

Prospective diagnostic performance of PET/CT using the novel fibroblast imaging tracer 18F-AlF-FAPI-74 versus standard of care 18F-FDG in inflammatory disorders.

Igg4 Related Disease trials by city

Other conditions